SCHEMBL5114468

SCHEMBL5114468

COC1Oc2c(c(=O)oc3ccc(C(C)C)cc23)C1c1c(O)c2cc(C(C)C)ccc2oc1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO1 P15559 7/20 0.37
CYP2C9 P11712 1/20 0.37
CRHBP P24387 1/20 0.37
CASP7 P55210 1/20 0.37
CASP6 P55212 1/20 0.37
CRHR2 Q13324 1/20 0.37
HIF1A Q16665 1/20 0.37
MGAM O43451 2/20 0.36
CSNK2A2 P19784 1/20 0.35
CSNK2B P67870 1/20 0.35
CSNK2A1 P68400 1/20 0.35
CASP3 P42574 1/20 0.34
SENP8 Q96LD8 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
SENP6 Q9GZR1 1/20 0.34
TBK1 Q9UHD2 3/20 0.34
MAOB P27338 3/20 0.33
PRNP P04156 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5125229 0.86 PRNP (0.42) NQO1CYP2C9MGAMCSNK2A2CSNK2B
SCHEMBL5341445 0.85 NQO1 (0.39) NQO1CYP2C9CRHBPCASP7CASP6
SCHEMBL5126126 0.85 NQO1 (0.48) NQO1CASP7CSNK2A2CSNK2BCSNK2A1
SCHEMBL5112347 0.84 NQO1 (0.47) NQO1MAOBPRNPRXFP1
SCHEMBL5115207 0.84 NQO1 (0.47) NQO1MGAMCSNK2A2CSNK2BCSNK2A1
SCHEMBL5120361 0.84 NQO1 (0.53) NQO1CYP2C9CSNK2A2CSNK2BCSNK2A1
SCHEMBL5119959 0.83 CSNK2A2 (0.39) NQO1CSNK2A2CSNK2BCSNK2A1MAOB
SCHEMBL5117858 0.81 NQO1 (0.46) NQO1CASP7CSNK2A2CSNK2BCSNK2A1
SCHEMBL5124909 0.80 NQO1 (0.37) NQO1MAOBPRNPRXFP1KDM4E
SCHEMBL6366185 0.77 NQO1 (0.45) NQO1HIF1AMGAMCSNK2A2CSNK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384975-B2 Substituted furochromenes, preparation thereof and their antiinflammatory action GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2008-06-10 US disclosed
US-20060148889-A1 Substituted furochromenes, preparation thereof and their antiinflammatory action PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2006-07-06 US disclosed
EP-1648902-A1 SUBSTITUTED FUROCHROMENES, PREPARATION THEREOF AND THEIR ANTIINFLAMMATORY ACTION PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) 2006-04-26 EP disclosed
WO-2005010007-A1 SUBSTITUTED FUROCHROMENES, PREPARATION THEREOF AND THEIR ANTIINFLAMMATORY ACTION PLIVA- ISTRAZIVACKI INSTITUT D.O.O. (HR) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148889-A1 Substituted furochromenes, preparation thereof and their antiinflammatory action CYP11B2, CYP11B1, LTC4S NQO1 60/4885CYP2C9 160/4885CRHBP 1779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.